SOSV SF & NY (Fka IndieBio)
VC Fund
San Francisco, United States
SOSV SF & NY (Fka IndieBio) is a VC fund in San Francisco focused on Biotechnology and Health Care. IndieBio, re-named SOSV SF and SOSV NY in 2026, are two of SOSV’s three deeply resourced facilities for deep tech founders. The third is SOSV's HAX, in Newark, NJ. SOSV is the most active deep tech venture capital firm globally.
- Total investments:
- 676
- Last investment:
- Lead investor:
- 3%
Last updated:
For AI agents: llms.txt
Industries SOSV SF & NY (Fka IndieBio) invests in
Stages SOSV SF & NY (Fka IndieBio) invests in
Countries SOSV SF & NY (Fka IndieBio) invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
| See all 11 contacts → | |||
Round size
- Seed
- $250k–$5M
- Pre-Seed
- $50k–$525k
- Convertible Note
- $150k–$950k
Investment Focus
Industry
- Biotechnology 212 (31%)
- Health Care 97 (14%)
- Medical 61 (9%)
- Life Science 53 (8%)
- Food and Beverage 36 (5%)
Stage
- Seed 263 (39%)
- Pre-Seed 110 (16%)
- Convertible Note 107 (16%)
- Series A 33 (5%)
- Series B 12 (2%)
Country
- United States 232 (34%)
- United Kingdom 20 (3%)
- Canada 19 (3%)
- Israel 10 (1%)
- Argentina 8 (1%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Mohan Iyer
Partner
|
Partner | Total investments: 34 | Find email | |
Arvind Gupta
Founder & Managing Director
|
Founder & Managing Director | Total investments: 274 | Find email | |
Fabian Schvartzman
Mentor
|
Mentor | Total investments: 0 | Find email | |
Jennifer O'Brien
Participant Batch 12
|
Participant Batch 12 | Total investments: 0 | Find email | |
Jun Axup
Scientific Director & Partner
|
Scientific Director & Partner | Total investments: 0 | Find email | |
| See all 11 team members → | ||||
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Giraffe Bio is a developer of biomolecular technology to improve efficiency and sustainability in critical mineral extraction. The company’s platform customizes biomolecules to each mine’s unique geology, enhancing metal recovery, reducing water use, and minimizing environmental impact. | $6.4M / Seed / Oct 13, 2026 | ||
| Transition Biomining is a metal ore mining technology company that offers data driven solutions for copper extraction and mining. | $6M / Seed / Jan 15, 2026 | ||
| FluoSphera is a discovery of efficient drugs with fewer adverse side effects and the reduction of animal experimentation, allowing companies to address the complexity of human physiological responses and protect populations from hazardous chemicals more effectively. | $1.4M / Seed / Jan 12, 2026 | ||
| Cellens is a medical device company that provides clarity and focus on cancer detection. Cellens is a Tufts University spinoff company dedicated to providing patients and doctors with clarity and confidence through noninvasive cancer screening. It was founded in 2019 and is based in Medford, Massachusetts. | $6.5M / Seed / Dec 23, 2025 | ||
| Foundational Bio is a biotech company engaged in the development of self-driving labs to enable large-scale discovery in the life sciences. | Seed / Dec 22, 2025 | ||
| Lingrove manufactures high-performance natural fiber composites from plant-based fibers and resins using a proprietary process and adaptable platform. Its line of veneer and panel products is called Ekoa, which is sold B2B to manufacturers in the commercial interiors, transportation, and construction space. Inspired by nature’s greatest material,old-growth wood, Lingrove seeks to reduce deforestation and embodied carbon of buildings. | Series B / Dec 16, 2025 | ||
| We are a biotech startup democratizing genomic sequencing applications with proprietary technology. We developed a reliable and robust solution to bring down the cost of applications in long-read sequencers. Our solution consists in a proprietary technology that enables the invention of a myriad of new long-read applications. | Seed / Nov 25, 2025 | ||
| Klona Biotech develops bioprinting platforms and technologies capable of producing functional, fibrous human tissue structures. | Seed / Nov 25, 2025 | ||
| We're developing personalized assays to determine the most suitable medication for cancer therapy at the patient level. Through our proprietary Drug Activity and Resistance Test, oncologists will be able to make data-driven decisions regarding cancer therapy selection based on patient-derived samples. Our goal is to democratize access toPrecision Oncology and improve cancer patients' lives. | $4.5M / Seed / Nov 24, 2025 | ||
| Gozen is to redefine how we engage with the world around us by promoting natural connection and a balance between creative expression and the sacredness of our earth. | Convertible Note / Nov 14, 2025 | ||
| See all 676 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does SOSV SF & NY (Fka IndieBio) invest in?
SOSV SF & NY (Fka IndieBio) invests primarily in Biotechnology, Health Care and Medical startups, most often at Seed and Pre-Seed stage. Most of the 676 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What round sizes does SOSV SF & NY (Fka IndieBio) invest in?
SOSV SF & NY (Fka IndieBio) typically joins rounds of $250k–$5M at Seed, $50k–$525k at Pre-Seed and $150k–$950k at Convertible Note. These are whole funding-round sizes, not SOSV SF & NY (Fka IndieBio)'s own check, which is rarely disclosed: the 10th–90th percentile of the confirmed public funding rounds SOSV SF & NY (Fka IndieBio) took part in.
How do I contact SOSV SF & NY (Fka IndieBio)?
Public channels for SOSV SF & NY (Fka IndieBio) include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at SOSV SF & NY (Fka IndieBio)?
The team at SOSV SF & NY (Fka IndieBio) includes Mohan Iyer (Partner), Arvind Gupta (Founder & Managing Director) and Fabian Schvartzman (Mentor), among 11 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
